Form 4: Adverum Biotechnologies Executive Acquires Stock Options

Rabia Gurses Ozden, Chief Medical Officer of Adverum Biotechnologies, acquired 44,010 stock options on August 2, 2024.

Summary

• On August 2, 2024, Rabia Gurses Ozden, the Chief Medical Officer of Adverum Biotechnologies, acquired 44,010 stock options.
• The options have an exercise price of $7.15.
• The options vest over three years, starting August 2, 2024, with one-third vesting on the first anniversary and the remainder vesting monthly thereafter.
• The expiration date for the options is August 1, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to an executive. It doesn't inherently indicate positive or negative sentiment, but rather a standard practice of executive compensation.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency into the transactions of company executives.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing performance that benefits the company's value.

Key Dates